Sigma-Tau Research Switzerland

Sigma-Tau Research Switzerland, now operating as Leadiant Biosciences SA, is a pharmaceutical company based in Mendrisio, Switzerland, that specializes in the development of therapies for rare and ultra-rare diseases. Originally the Swiss research hub for the Italian Sigma-Tau Group, the company was rebranded in 2017 following the merger of Sigma-Tau and Alfa Wassermann to form Alfasigma. The company focuses on metabolic and genetic disorders, managing a portfolio of orphan drugs that includes treatments for cystinosis, adenosine deaminase deficiency (ADA-SCID), and cerebrotendinous xanthomatosis (CTX). Leadiant Biosciences is recognized for its historical expertise in PEGylation technology and enzyme replacement therapies. The Swiss site remains a critical center for the group's global clinical development and regulatory activities.